Compare TMQ & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMQ | URGN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 785.2M | 922.1M |
| IPO Year | N/A | 2017 |
| Metric | TMQ | URGN |
|---|---|---|
| Price | $5.70 | $19.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 6.6M | 728.3K |
| Earning Date | 02-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $96,516,000.00 |
| Revenue This Year | N/A | $26.47 |
| Revenue Next Year | N/A | $110.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.00 |
| 52 Week Low | $1.13 | $3.42 |
| 52 Week High | $11.29 | $30.00 |
| Indicator | TMQ | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 44.27 |
| Support Level | $4.93 | $18.97 |
| Resistance Level | $7.25 | $22.07 |
| Average True Range (ATR) | 0.60 | 1.31 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 31.25 | 49.24 |
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.